These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29337165)

  • 1. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
    Ma B; Barth A; McHale CM; Lai MT
    Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
    Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
    J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
    Margot NA; Johnson A; Miller MD; Callebaut C
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
    Margot N; Ram R; Abram M; Haubrich R; Callebaut C
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
    Cobb DA; Smith N; Deodhar S; Bade AN; Gautam N; Shetty BLD; McMillan J; Alnouti Y; Cohen SM; Gendelman HE; Edagwa B
    Nat Commun; 2021 Sep; 12(1):5458. PubMed ID: 34531390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
    García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
    J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
    Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
    Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Bae J; Tantawy M; Gong Y; Langaee T; Lartey M; Ganu V; Tachi K; Ojewale O; Obo-Akwa A; Boamah I; Bushman LR; Ellison L; Yang H; Anderson PL; Kwara A
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0054924. PubMed ID: 39078131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression.
    Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A
    AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    Cox S; Margot N; Callebaut C
    J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
    Duwal S; Schütte C; von Kleist M
    PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.